Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Arcutis Biotherapeutics Inc shares valued at $53,988 were sold by Burnett Patrick on Aug 08 ’25. At $14.03 per share, Burnett Patrick sold 3,847 shares. The insider’s holdings dropped to 108,999 shares worth approximately $1.74 million following the completion of this transaction.
Also, Topper David Joseph purchased 41,979 shares, netting a total of over 611,936 in proceeds.
Before that, Burnett Patrick had added 3,847 shares to its account. In a trade valued at $53,989, the Officer bought Arcutis Biotherapeutics Inc shares for $14.03 each.
As published in their initiating research note from Goldman on July 25, 2025, Arcutis Biotherapeutics Inc [ARQT] has been a Neutral and the price target has been revised to $18. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in late December. As of August 28, 2024, Jefferies has initiated its “Buy” rating for ARQT. Earlier on January 03, 2024, Mizuho upgraded its rating. Their new recommendation was “a Buy” for ARQT stock which previously was a “a Neutral”.
Analyzing ARQT Stock Performance
On last trading session, Arcutis Biotherapeutics Inc [NASDAQ: ARQT] rose 2.24% to $15.98. The stock’s lowest price that day was $15.15, but it reached a high of $16.14 in the same session. During the last five days, there has been a surge of approximately 13.17%. Over the course of the year, Arcutis Biotherapeutics Inc shares have jumped approximately 68.39%. Shares of the company reached a 52-week high of $17.75 on 03/25/25 and a 52-week low of $11.13 on 02/11/25.
Support And Resistance Levels for Arcutis Biotherapeutics Inc (ARQT)
According to the 24-hour chart, there is a support level at 15.37, which, if violated, would cause prices to drop to 14.75. In the upper region, resistance lies at 16.37. The next price resistance is at 16.75. RSI (Relative Strength Index) is 60.53 on the 14-day chart, showing neutral technical sentiment.
Is Arcutis Biotherapeutics Inc subject to short interest?
Stocks of Arcutis Biotherapeutics Inc saw a sharp steep in short interest on 2025-07-31 dropping by -3.96 million shares to 16.64 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 20.6 million shares. A decline of -23.79% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 10.75 of the overall float, the days-to-cover ratio (short ratio) decline to 10.75.
Which companies own the most shares of Arcutis Biotherapeutics Inc (ARQT)?
In terms of Arcutis Biotherapeutics Inc share price expectations, FactSet research, analysts set an average price target of 19 in the next 12 months, up nearly 21.56% from the previous closing price of $15.63. Analysts anticipate Arcutis Biotherapeutics Inc stock to reach 19 by 2025, with the lowest price target being 19. In spite of this, 3 analysts ranked Arcutis Biotherapeutics Inc stock as Buy at the end of 2025. On October 26, 2023, Mizuho assigned a price target of “a Neutral” to the stock and downgraded coverage with a $4.
